"10.1371_journal.pone.0094167","plos one","2014-04-14T00:00:00Z","Larissa J Lee; Elena Ratner; Mohamed Uduman; Kathryn Winter; Marta Boeke; Kathryn M Greven; Stephanie King; Thomas W Burke; Kelly Underhill; Harold Kim; Raleigh J Boulware; Herbert Yu; Vinita Parkash; Lingeng Lu; David Gaffney; Adam P Dicker; Joanne Weidhaas","Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America; Department of Gynecologic Oncology, Yale University, New Haven, Connecticut, United States of America; Interdepartmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, United States of America; Statistical Center, Radiation Therapy Oncology Group (RTOG), Philadelphia, Pennsylvania, United States of America; Department of Radiation Oncology, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States of America; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Radiation Oncology, Benefis Sletten Cancer Institute, Great Falls, Montana, United States of America; Department of Radiation Oncology, Wayne State University Karamanos Cancer Center, Detroit, Michigan, United States of America; Radiation Oncology, South Carolina Oncology Associates, Columbia, South Carolina, United States of America; Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States of America; Department of Chronic Disease and Epidemiology, Yale University, New Haven, Connecticut, United States of America; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America; Department of Therapeutic Radiology, Yale University, New Haven, Connecticut, United States of America; Department of Radiation Oncology, University of Utah Huntsman Cancer Hospital, Salt Lake City, Utah, United States of America; Department of Pathology, Yale University, New Haven, Connecticut, United States of America","Conceived and designed the experiments: DG AD JW. Performed the experiments: ER MB VP. Analyzed the data: MU KW L. Lee. Contributed reagents/materials/analysis tools: HY L. Lu DG AD. Wrote the paper: L. Lee JW. Involved in the inception of the RTOG 9708 and 9905 trials (and are included per RTOG publication policy): KG SK TB KU HK RB.","Dr. Weidhaas and Dr. Slack discovered the KRAS-variant, which is patented by Yale University. This patent is called “Genetic Lesion Associated with Cancer”, and the number is 8,221,980. It has been licensed to a company, Mira Dx, that Dr. Slack and Dr. Weidhaas co-founded. Neither Dr. Slack nor Dr. Weidhaas are employed or paid by Mira Dx, but act as unpaid scientific consultants. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.","2014","04","Larissa J Lee","LJL",17,TRUE,3,3,3,1,TRUE,TRUE,FALSE,0,NA,FALSE
